Monthly
US$200
Billed every month
Sign in to subscribeMagnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
As of 13 November 2026, for Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution, 8 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 1 holder.
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 applicationAccepted: 3 applicationsNo longer listed under review: 1 applicationNotification delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders1View records ↓
Under-review filings8View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers40View records ↓
API companies with A status0View records ↓
Chemical-drug catalogue
Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 1 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Ji Chuan Pharma Group Co., Ltd. romanized | Ji Chuan Pharma Group Co., Ltd. romanized | 国药准字H20223027 | 2022/01/30 | See source | Generic approved under the new chemical-drug registration classification | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 40 distinct approval numbers and 40 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Beijing SL Pharmaceutical Co., Ltd. | 国药准字H20264944 | See source | Category B | XA06ADL397X019010100148 | NHSA |
| Guangdong Long Fu Pharma Co., Ltd. romanized | 国药准字H20263215 | See source | Category B | XA06ADL397X019010100290 | NHSA |
| Zhejiang Guo Jing Pharma Co., Ltd. romanized | 国药准字H20265417 | See source | Category B | XA06ADL397X019010104634 | NHSA |
| Guangxi Wei Wei Pharmaceutical Co., Ltd. romanized | 国药准字H20265438 | See source | Category B | XA06ADL397X019010105237 | NHSA |
| Jiangxi Sheng Xiang Pharmaceutical Co., Ltd. romanized | 国药准字H20263795 | See source | Category B | XA06ADL397X019010105355 | NHSA |
| Shandong Lang Nuo Pharmaceutical Co., Ltd. romanized | 国药准字H20264316 | See source | Category B | XA06ADL397X019010110323 | NHSA |
| Tian Sheng (Xiamen) Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20265186 | See source | Category B | XA06ADL397X019010186658 | NHSA |
| Guangdong Da Zhong Pharmaceutical Co., Ltd. romanized | 国药准字H20255104 | See source | Category B | XA06ADL397X019010100273 | NHSA |
| Wuhan Tong Ji Xian Dai Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20253056 | See source | Category B | XA06ADL397X019010100555 | NHSA |
| Jiangsu Vanguard Pharmaceutical Co., Ltd. | 国药准字H20253543 | See source | Category B | XA06ADL397X019010101503 | NHSA |
| NANJING ZENKOM PHARMACEUTICAL CO.,LTD. | 国药准字H20255040 | See source | Category B | XA06ADL397X019010101599 | NHSA |
| Hebei Hua Chen Pharma Group Co., Ltd. romanized | 国药准字H20255517 | See source | Category B | XA06ADL397X019010102617 | NHSA |
| Hebei He Du Pharma Co., Ltd. romanized | 国药准字H20255028 | See source | Category B | XA06ADL397X019010102680 | NHSA |
| Shijiazhuang Shi Hua Xin Pharma Co., Ltd. romanized | 国药准字H20255032 | See source | Category B | XA06ADL397X019010102753 | NHSA |
| Yun Peng Pharmaceuticals Group Co., Ltd. romanized | 国药准字H20255175 | See source | Category B | XA06ADL397X019010102968 | NHSA |
| Shandong Qidu Pharmaceutical Co., Ltd. | 国药准字H20253358 | See source | Category B | XA06ADL397X019010104145 | NHSA |
| Anhui Huan Qiu Pharma Co., Ltd. romanized | 国药准字H20255300 | See source | Category B | XA06ADL397X019010104303 | NHSA |
| Zhejiang Kai Run Pharma Co., Ltd. romanized | 国药准字H20255103 | See source | Category B | XA06ADL397X019010104649 | NHSA |
| Shenyang Tian Bang Pharma Co., Ltd. romanized | 国药准字H20255021 | See source | Category B | XA06ADL397X019010110021 | NHSA |
| Ren He Yi Kang Group Co., Ltd. romanized | 国药准字H20253996 | See source | Category B | XA06ADL397X019010183033 | NHSA |
| Suzhou Lang Ke Bio Technology Co., Ltd. romanized | 国药准字H20253542 | See source | Category B | XA06ADL397X019010183485 | NHSA |
| Jiangsu Guang Cheng Pharma Co., Ltd. romanized | 国药准字H20255051 | See source | Category B | XA06ADL397X019010183611 | NHSA |
| Zhejiang Bai Dai Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20255524 | See source | Category B | XA06ADL397X019010184211 | NHSA |
| Guangzhou Shi Yi Yuan Pharmaceuticals Co., Ltd. romanized | 国药准字H20255031 | See source | Category B | XA06ADL397X019010184691 | NHSA |
| Guangzhou He He Pharmaceuticals Co., Ltd. romanized | 国药准字H20256254 | See source | Category B | XA06ADL397X019010185013 | NHSA |
| Suzhou Erye Pharmaceutical Co., Ltd | 国药准字H20254941 | See source | Category B | XA06ADL397X019010185068 | NHSA |
| Chengdu Mi Zi Biopharmaceuticals Technology Co., Ltd. romanized | 国药准字H20255294 | See source | Category B | XA06ADL397X019010185135 | NHSA |
| Wuhan Tong Ji Xian Dai Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20253056 | See source | Category B | XA06ADL397X019010200555 | NHSA |
| Shandong Qidu Pharmaceutical Co., Ltd. | 国药准字H20253358 | See source | Category B | XA06ADL397X019010204145 | NHSA |
| Jiangsu Guang Cheng Pharma Co., Ltd. romanized | 国药准字H20255051 | See source | Category B | XA06ADL397X019010283611 | NHSA |
| Hunan Qian Jin Xiang Jiang Pharma Co., Ltd. romanized | 国药准字H20253062 | See source | Category B | XA06ADL397X019010284109 | NHSA |
| Wuhan Tong Ji Xian Dai Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20253056 | See source | Category B | XA06ADL397X019010300555 | NHSA |
| Guangzhou Da Guang Pharmaceutical Co., Ltd. romanized | 国药准字H20249371 | See source | Category B | XA06ADL397X019010100548 | NHSA |
| Ji Chuan Pharma Group Co., Ltd. romanized | 国药准字H20223027 | See source | Category B | XA06ADL397X019010101453 | NHSA |
| Yang Zi Jiang Pharma Group Shanghai Hai Ni Pharma Co., Ltd. romanized | 国药准字H20223102 | See source | Category B | XA06ADL397X019010101747 | NHSA |
| IPSEN CONSUMER HEALTHCARE | 国药准字HJ20220094 | See source | Category B | XA06ADL397X019010183508 | NHSA |
| Wei Sheng Yuan (Xiamen) Bio Technology Co., Ltd. romanized | 国药准字H20249740 | See source | Category B | XA06ADL397X019010183535 | NHSA |
| Chongqing Jian Neng Pharma Group Co., Ltd. romanized | 国药准字H20249699 | See source | Category B | XA06ADL397X019010183692 | NHSA |
| Changchun Lan Jiang Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20249385 | See source | Category B | XA06ADL397X019010183864 | NHSA |
| Zhejiang Gao Zhi Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20249372 | See source | Category B | XA06ADL397X019010184221 | NHSA |
| Zhejiang Heng Yan Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20249703 | See source | Category B | XA06ADL397X019010184227 | NHSA |
| Nanjing Zhi He Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20249629 | See source | Category B | XA06ADL397X019010184650 | NHSA |
| Xizang Ao Si Bi Xiu Pharmaceuticals Co., Ltd. romanized | 国药准字H20249746 | See source | Category B | XA06ADL397X019010184724 | NHSA |
| Ji Chuan Pharma Group Co., Ltd. romanized | 国药准字H20223027 | See source | Category B | XA06ADL397X019010201453 | NHSA |
| Hainan Si Da Pharmaceutical Co., Ltd. romanized | 国药准字H20266115 | See source | Category B | XA06ADL397X019010105816 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 8 filings and 7 distinct first applicants.
Generic 5 · Supplement 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Nanjing Healthnice Pharmaceutical Technology Co., Ltd; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CYHS2600391 | Generic | 2026/02/06 | Not stated by source | CDE |
| Liaoning Da Xiong Pharmaceutical Co., Ltd. romanized | CYHS2602246 | Generic | 2026/09/09 | Not stated by source | CDE |
| MAYOLY PHARMA FRANCE; MAYOLY INDUSTRIE | JYHB2600344 | Supplement | 2026/06/24 | Not stated by source | CDE |
| Ha Yao Group Bio Gong Cheng Co., Ltd. romanized | CYHS2504378 | Generic | 2025/12/24 | Not stated by source | CDE |
| Xi Zhou Pharmaceuticals Technology (Zhejiang) Co., Ltd. romanized; Zhejiang Bei Sheng Pharma Han Sheng Pharmaceutical Co., Ltd. romanized | CYHS2502037 | Generic | 2025/06/10 | Not stated by source | CDE |
| Hubei Wu Shi Pharma Co., Ltd. romanized | CYHS2501165 | Generic | 2025/03/25 | Not stated by source | CDE |
| MAYOLY PHARMA FRANCE; MAYOLY INDUSTRIE | JYHB2600594 | Supplement | 2026/11/04 | Not stated by source | CDE |
| Chi Feng Yuan Sheng Pharma Co., Ltd. romanized; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CYHB2602048 | Supplement | 2026/11/11 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Nanjing Healthnice Pharmaceutical Technology Co., Ltd; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CYHS2600391 | Generic | 2026/02/06 | Not stated by source | CDE |
| Liaoning Da Xiong Pharmaceutical Co., Ltd. romanized | CYHS2602246 | Generic | 2026/09/09 | Not stated by source | CDE |
API registrations
Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
-
2026/11/11No longer listed under review
Hubei Hai Mei Na Pharmaceuticals Technology Co., Ltd. romanized; Hubei Wei Sen Pharmaceutical Co., Ltd. romanized
CYHS2501365
Fact date: 2026/11/11 · Site observation date: 2026/11/11
Accepted: 2025/04/09
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/11/11Accepted
Chi Feng Yuan Sheng Pharma Co., Ltd. romanized; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized
CYHB2602048
Fact date: 2026/11/11 · Site observation date: 2026/11/12
View source ↗ -
2026/11/04Notification delivery
Chengdu Ya Zhong Biopharmaceutical Co., Ltd. romanized
CYHS2504013
Fact date: 2026/11/04 (Publication date) · Publication date: 2026/11/04 · Site observation date: 2026/11/04
Notification delivered; the specific outcome remains to be checked.
View source · Table row 10 ↗ -
2026/11/04Accepted
MAYOLY PHARMA FRANCE; MAYOLY INDUSTRIE
JYHB2600594
Fact date: 2026/11/04 · Site observation date: 2026/11/05
View source ↗ -
2026/10/26Marketing application approved
Hubei Min Kang Pharma Group Co., Ltd. romanized
CYHS2500938 · 国药准字H20266415
Fact date: 2026/10/26 · Publication date: 2026/10/27 · Site observation date: 2026/11/03
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 35 ↗ -
2026/09/09Accepted
Liaoning Da Xiong Pharmaceutical Co., Ltd. romanized
CYHS2602246
Fact date: 2026/09/09 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/13 06:41
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy